Liver under Constant Attack – From Fat to Viruses Abstracts Poster Abstracts

185 Pages·2008·1.03 MB·English

99497_Falk_US_Symposium167_Mainz_e:1 01.09.2008 15:59 Uhr Seite 1
7
6
1
m Falk Symposium 167
u
i
s
o
p
m
y
S

k Liver under Constant Attack –
l
a
F
From Fat to Viruses
September 20 – 21, 2008
Congress Center Mainz
Innovative Drugs
for bowel and liver diseases
Modern formulations and specially designed delivery systems
ensure targeted release of the active drug
s
t
Scientific Dialogue c
a
in the interest of therapeutic progress tr
s
b
More than 200 Falk Symposia and Workshops, A

attended by some 100,000 participants from over 100 countries since 1967 r
e
t
s
Over 13,000 continuing medical education seminars, o
P Abstracts
attended by more than one million physicians and patients in Germany alone /
s
t
c
Comprehensive literature service with more than 200 publications a Poster Abstracts
r
for healthcare professionals as well as patients and their families t
s
b
A
www.falkfoundation.com www.drfalkpharma.com
Leinenweberstr. 5 79108 Freiburg Germany Tel [phone] Fax [phone] Mail [email protected]
Abstracts of Invited Lectures
Poster Abstracts

Falk Symposium 167

LIVER UNDER CONSTANT ATTACK –
FROM FAT TO VIRUSES

Mainz (Germany)
September 20 – 21, 2008

Scientific Organization:
C.P. Day, Newcastle (Great Britain)
P.R. Galle, Mainz (Germany)
A.W. Lohse, Hamburg (Germany)
S.S. Thorgeirsson, Bethesda (USA)
CONTENTS

Page

Session I

Viral liver diseases

Chair:
C.P. Day, Newcastle
M.P. Manns, Hannover

State-of-the-Art Lecture
Antiviral immunity and viral escape mechanisms
B. Rehermann, Bethesda 19 – 20

HCV – Immunology (No abstract)
C. Ferrari, Parma

Hepatitis C therapy
I.M. Jacobson, New York 21 – 27

Hepatitis B virus infection – Virology
M. Dandri, Hamburg 28

The therapy of hepatitis B – State-of-the-Art
M.P. Manns, K. Wursthorn, Hannover 29 – 30

Fat and viral liver disease
F. Negro, Geneva 31 – 33

Session II

Interdisciplinary hepatology

Chair:
H. Lang, Mainz
A.W. Lohse, Hamburg

State-of-the-Art Lecture
Immunology and tolerance in liver transplantation
A.W. Lohse, Hamburg 37

Science and art of immunosuppression in liver transplantation
H.J. Schlitt, Regensburg 38

3
Molecular pathogenesis and prognostic prediction of liver cancer
S.S. Thorgeirsson, Bethesda 39

Signal transduction pathways and targeted therapies in HCC
P.R. Galle, Mainz 40 – 41

Cholangiocellular carcinoma – Diagnostic tools, medical
strategy and new options
J. Mössner, M. Wiedmann, Leipzig 42

Cholangiocellular carcinoma – Role of surgery
G. Otto, Mainz 43

Session III

Gut attack: Liver in LPS crossfire

Chair:
S.S. Thorgeirsson, Bethesda
P.R. Galle, Mainz

State-of-the-Art Lecture
NF-κB, a crucial factor in mediating liver diseases
C. Trautwein, Aachen 47

Lymphocyte recruitment to the liver; molecular insights into the
pathogenesis of liver injury and hepatitis
D.H. Adams, Birmingham 48

LPS in liver disease
G. Szabo, Worcester 49

Alcoholic hepatitis
H. Tilg, Hall/Tirol 50

IBD and liver diseases
M.F. Neurath, Mainz 51

NASH – Therapeutic intervention
C.P. Day, Newcastle 52
4
Session IV

Fibrosis, cirrhosis and portal hypertension

Chair:
J.F. Riemann, Ludwigshafen
D. Patch, London

State-of-the-Art Lecture
Molecular mechanisms of fibrosis – Targets of therapy
J.P. Iredale, Edinburgh 55 – 56

Assessment of liver fibrosis

Non-invasive assessment of liver fibrosis by transient
elastography
M. Beaugrand, Bondy 57

Non-invasive – Serum biomarkers (No abstract)
W. Rosenberg, London

Gold standard biopsy?
U.W. Denzer, Hamburg 58

Variceal bleeding
T. Sauerbruch, Bonn 59

Ascites and hepatorenal syndrome
V. Arroyo-Perez, Barcelona 60

TIPS
D. Patch, London 61 – 64

List of Speakers, Moderators and Scientific Organizers 65 – 67
5
Poster Abstracts

1. Non-invasive assessment of liver fibrosis in patients with chronic hepatitis C
T. Alempijevic, R. Jesic, I. Jovanovic, D. Popovic, N. Kovacevic, M. Krstic
(Belgrade, SRB)

2. Can hepatocytes originate from umbilical cord blood stem cells?
D.I. Andreeva, T.S. Yilmaz, I.M. Gazizov, M.S. Kaligin, S. Abdulkhakov,
A.P. Kiassov (Kazan, R)

3. The Ursofalk® effectiveness in the complex therapy in patients with chronic viral
hepatitis C in association with non-alcoholic steatosis
N. Antonova, N. Bodrug, G. Bivol (Chisinau, MOL)

4. Efficiency of treatment with Ursofalk® in patients with gallbladder stones
associated with liver cirrhosis
O. Arhip (Botosani, RO)

5. The effect of insulin sensitizing agents (ISA) on "protein C" and on paraoxonase
mRNA expression in rats with fatty liver
N. Assy, T. Shatil, M. Grozovski (Safed, Karmil, Haifa, IL)

6. Ursodeoxycholic acid administration in hepatitis C virus non-responders with
cholestasis
C. Banciu, L.M. Susan, L. Marian, A. Pacurari, I. Romosan (Timisoara, RO)

7. Use of clondine in cirrhotic patients with large diuretic resistant ascitis –
Prospective pilot study
C. Banciu, L.M. Susan, V. Vacariu, C. Dascau, L. Marian, I. Romosan
(Timisoara, RO)

8. The value of liver biopsy in diagnosis of congenital hepatic fibrosis –
Comparative aspects in two young patients with progressive cholestatis
G. Becheanu, M. Dumbrava, A. Nicolae, T. Marinescu, C. Toader, M. Diculescu
(Bucharest, RO)

9. The CC chemokine RANTES (CCL5) is an important mediator of fibrosis in
murine and human chronic liver injury
M.-L. Berres, A. Rüland, M. Moreno Zaldivar, P. Schmitz, D. Scholten,
N. Gassler, C. Weber, R. Weiskirchen, C. Trautwein, H.E. Wasmuth
(Aachen, D)

10. The role of HBcor-Ab in the donor blood testing
D. Beshimova, D.S. Enaleeva, E.G. Gaifullina (Kazan, R)

11. Overexpression of cytochrome P450 2E1 contributes to anti-tubercular drugs
(isoniazid and rifampicin) induced hepatic steatosis in mice model
A. Biswas, S. Ghatak, S. Banerjee, S. Dutta, G.K. Dhali, A. Chowdhury,
A.K. Santra (Kolkata, IND)
7
12. Liver dysfunction caused by abdominal compartment syndrome in critically ill
surgical patients
Z. Bodnár, S. Sipka, Z. Kincses (Debrecen, H)

13. Immunological effects of Ursofalk® administered on the patients with acute viral
hepatitis C
N. Bodrug, N. Antonova, G. Bivol, A. Scorpan (Chisinau, Kishinev, MOL)

14. Effects of TNFα blocking antibody on rat experimental alcoholic steatohepatitis
V.U. Buko, P. Kirvel, O. Lukivskaya, E.E. Naruta, M. Goretskaya (Grodno, WR)

15. Progression of liver fibrosis due to viral hepatitis C in renal transplant recipients
L.O. Cantadori, K.I.R. Coelho, L. Silveira, C.A. Caramori, M.F.C.C. Carvalho,
J. Defaveri, G.F. Silva (Botucatu, BR)

16. The role of atypical antineutrophil cytoplasmic antibodies in the relationship
between rheumatoid arthritis and primary sclerosing cholangitis
A. Caraba, V. Crisan, S.R. Gotia, I. Romosan (Timisoara, RO)

17. Simvastatin reduces the liver biochemistry abnormalities in non-alcoholic fatty
liver disease
A. Caraba, S.R. Gotia, I. Romosan (Timisoara, RO)

18. Steatosis in chronic hepatitis B patients is associated with host metabolic
factors but is not associated with the treatment outcome
P. Chan, P. Ip, T. Yau, M.-F. Yuen, D.-K.-H. Wong, V.-W.-S. Ngai, C.L. Lai
(Hong Kong, HK)

19. Embolization of the splenic artery in advanced liver cirrhosis: Hemodynamic
changes
S. Chooklin (Lviv, UKR)

20. Is it any relation between non-alcoholic fatty liver disease and polycystic ovary
syndrome?
C. Cijevschi Prelipcean, C. Mihai, M. Dranga, D. Chirita, P. Burca, E. Zbranca
(Iasi, RO)

21. Histological profile and viral level in patients with chronic hepatitis C with normal
and elevated ALT levels
M. Cornianu, A. Dema, S. Taban, D. Lazar, E. Lazar, S. Costi, I. Marincu,
I. Sporea, A. Goldis (Timisoara, RO)

22. Morphological, biochemical and viral parameters in chronic hepatitis C virus
(HCV)
M. Cornianu, A. Dema, S. Taban, D. Lazar, E. Lazar, I. Marincu, A. Goldis
(Timisoara, RO)

23. Correlation between steatosis and biological parameters in chronic hepatitis C
M. Cornianu, A. Dema, S. Taban, D. Lazar, E. Lazar, R. Sirli, I. Sporea
(Timisoara, RO)
8
24. Hepatocyte proliferative activity in chronic liver damage as evaluated by Ki67
(MIB-1): Relationship to etiology, disease activity, iron storage and lipid
peroxidation
M. Cornianu, D. Lazar, A. Dema, S. Taban, E. Lazar, A. Faur, C.V. Gurban,
I. Sporea (Timisoara, RO)

25. Cryoglobulinemia and chronic hepatitis C
D. Damian, M. Grigorescu, M.D. Grigorescu, T. Zaharie, T. Mocanu
(Cluj-Napoca, RO)

26. The relative risk of developing advanced fibrosis in patients with dyslipidemias
M. Deac, R. Mihaila, E.C. Rezi, L. Nedelcu, O. Fratila, C. Domnariu, L. Bera,
R. Mihaila (Sibiu, Brasov, Oradea, RO)

27. The efficiency and safety of the treatment with bezafibrate in a group of patients
with virus C chronic hepatitis and normal lipids
M. Deac, C. Cipaian, D. Vulcu, C. Beca, O. Petrascu, R. Mihaila, A. Deac
(Sibiu, RO)

28. Increased ferritin levels during antiviral therapy for chronic hepatitis C.
Relationship with ALT flare and ribavarin-induced hemolysis
M. Delle Monache, L. Baiocchi, R. Cecere, A. Salso, M. Carbone,
F. De Leonardis (Rome, I)

29. The role of liver transplantation in porphyria
J.K. Dowman, M. Badminton, P.N. Newsome (Birmingham, Cardiff, GB)

30. Smad7 – A regulator of tumor promoting versus tumor suppressive TGF-β
signals in hepatocytes
J. Dzieran, B. Bauche, A. Tannapfel, S. Dooley, N.M. Meindl-Beinker
(Mannheim, Bochum, D)

31. Enteric dentritic cells determine recruitment of mucosal T cells to the liver in
primary sclerosing cholangitis
B. Eksteen, J.R. Mora, S.M. Curbishley, A.I. Aspinall, U.H. von Andrian,
D.H. Adams (Birmingham, GB; Boston, USA; Calgary, CDN)

32. Increased visfatin levels in non-alcoholic fatty liver disease are associated with
insulin resistance and liver histology
C.N. Ercin, Z. Yesilova, K. Dagalp, A. Uygun, Y. Karslioglu, S. Tapan, E. Oztas,
G. Kilciler, Z. Polat, S. Bagci (Ankara, TR)

33. Autoimmune reactions and phagocytosis in chronic viral hepatitis C
V. Fazylov, E.G. Gaifullina, J.R. Mangusheva (Kazan, R)

34. Hepatic cirrhosis of the HCV etiology as the cause of fatal outcome in
HIV-infected patients
E.G. Gaifullina, O. Romanenko, M. Makarova (Kazan, R)
9
35. Perisinusoidal cells expressing stem cell properties after partial hepatectomy in
rats
I.M. Gazizov, M.S. Kaligin, D.I. Andreeva, T.S. Yilmaz, A.A. Gumerova,
A.P. Kiassov (Kazan, R)

36. Additional application of interferon-alpha after complete destruction of
hepatocellular carcinoma (HCC): Influence on local tumor progression (LTP)
J. Genov, N. Grigorov, R. Mitova, B. Golemanov, L. Dinkov, M. Donov
(Sofia, BG)

37. Factors predicting complete destruction (CD), local tumor progression (LTP)
and survival after percutaneous ablation of hepatocellular carcinoma (HCC)
J. Genov, N. Grigorov, R. Mitova, B. Golemanov, L. Dinkov, M. Donov
(Sofia, BG)

38. A case with recurrent cholangiocellular carcinoma (CCC): 63-months follow-up
after complete radiofrequency ablation (RFA)
J. Genov, N. Grigorov, R. Mitova, B. Golemanov, L. Dinkov (Sofia, BG)

39. Therapeutic options in patients with non-alcoholic steatohepatitis
A. Genunche-Dumitrescu, D. Badea, P. Mitrut, M. Badea, C. Zamfir
(Craiova, RO)

40. Fulminant hepatic failure – Clinical findings of Wilson disease in childhood
M. Georgieva, D. Konstantinova, A. Atanassova, M. Jeleva, A. Savov
(Sofia, Varna, BG)

41. Real-time elastography – Clinical usefulness in patients with chronic hepatitis C
L. Gheorghe, S. Iacob, R. Iacob, G. Becheanu, M. Dumbrava (Bucharest, RO)

42. Molecular characterization of occult HBV isolated from HCV-infected patients
from eastern part of India
S. Ghosh, S. Sarkar, S.K. Bandyopadhyay, A. Santra, K. Das, S. Banerjee,
A. Chowdhury, S. Datta (Kolkata, IND)

43. The prevalence of HBV and HCV infection in blood donors from Timisoara
A. Goldis, I. Ratiu, D. Lazar, R. Goldis, I. Dan, D. Koukoulas, C. Constantea
(Timisoara, RO)

44. Epidemiological aspects of HBV infection in the western part of Romania
R. Goldis, D. Lazar, I. Ratiu, A. Goldis (Timisoara, RO)

45. Precipitating factors of chronic hepatic encephalopathy in liver diseases patients
C. Gorun, L.M. Susan, C. Banciu, A. Pacurari, V. Ancusa, G. Savoiu,
I. Romosan (Timisoara, RO)

46. A two year longitudinal study of the extrahepatic manifestations associated with
hepatitis C infection
C. Gorun, L.M. Susan, C. Banciu, A. Pacurari, G. Savoiu, V. Ancusa,
I. Romosan (Timisoara, RO)
10
47. Chemoembolisation combined with pravastatin improves survival in patients
with hepatocellular carcinoma
H. Graf, C. Jüngst, G. Straub, S. Dogan, R.-T. Hoffmann, T. Jakobs, M. Reiser,
T. Waggershauser, T. Helmberger, A. Walter, A. Walli, D. Seidel, B. Göke,
D. Jüngst (Landshut, Munich, D; Zurich, CH)

48. The contribution of ultrasound and scintigraphy to the differential diagnosis of
benign focal liver lesions in chronic liver diseases
I. Grigorescu, M.D. Grigorescu, Z. Sparchez, M. Dragoteanu, O. Pascu
(Cluj-Napoca, RO)

49. Differential diagnosis of hypo- and isoechoic hepatic masses – A study of
56 patients
I. Grigorescu, Z. Sparchez, M.D. Grigorescu, M. Dragoteanu, O. Pascu
(Cluj-Napoca, RO)

50. Liver function and bile duct disorders in the course of inflammatory bowel
disease in children
U. Grzybowska-Chlebowczyk, S. Wiecek, H. Wos, M. Kajor, M. Szymanska,
J. Kowol (Katowice, PL)

51. Kinetics of mast cells, macrophages, VEGF, TNF-alpha and TGF-beta1 in liver
cirrhosis
M.V. Gulubova, P. Hadjipetkov (Stara Zagora, BG)

52. The role of myofibroblasts in intrahepatic bile ducts changes during chronic viral
hepatitis and primary biliary cirrhosis
A.A. Gumerova, L. Fatkheeva, S. Abdulkhakov, M.A. Titova, A.P. Kiassov
(Kazan, R)

53. Liver fibrosis in children with chronic hepatitis C (CHC) in Belarus
M. Halabarodzka, A. Klyuchareva, T. Rayeuneva, S. Kletski (Minsk, WR)

54. The prognosis of glycoregulation disturbances in liver cirrhosis
B. Hanescu, D. Sampelean, A. Han, F. Casoinic (Cluj-Napoca, RO)

55. Toll-like receptor 4-dependent but MyD88-independent pathways mediate
alcoholic liver injury in mice
I. Hritz, A. Velayudham, D. Catalano, S. Dolganiuc, P. Mandrekar,
E. Kurt-Jones, G. Szabo (Budapest, H; Worcester, USA)

56. Early recurrent hepatitis C following liver transplantation – Independent
predictor of patient survival
S. Iacob, L. Gheorghe, D. Hrehoret, G. Becheanu, V. Herlea, I. Popescu
(Bucharest, RO)

57. The efficacy of the treatment with Aminoplasmal-Hepa in hepatic
encephalopathy in patients with liver cirrhosis
V. Istrati, V. Dumbrava, L. Condratchi, S. Chislari (Chisinau, MOL)
11